Products for Research Use Only

Pegcetacoplan (acetate)

CAT: 0804-HY-P3252A-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-P3252A-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Pegcetacoplan acetate is a pegylated complement C3 inhibitor peptide. Pegcetacoplan acetate acts by binding with complement component 3 (C3) and its activation fragment C3b. Pegcetacoplan acetate can be used for the research of complement-mediated diseases, including age-related macular degeneration, C3 glomerulopathy, Geographic atrophy (GA) and autoimmune haemolytic anaemia[1][2].
UNSPSC
12352209
Target
Complement System
Type
Peptides
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/pegcetacoplan-acetate.html
Purity
99.92
Solubility
3 M Sodium Acetate Solution (pH 5.2) : 12.5 mg/mL|DMSO : 50 mg/mL (ultrasonic)
Smiles
[Pegcetacoplan(acetate)]
Molecular Formula
(C2H4O) nC170H248N50O47S4.xC2H4O2
References & Citations
[1]David S Liao, et al. Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial. Ophthalmology. 2020 Feb;127 (2) :186-195.|[2]Sheridan M Hoy, et al. Pegcetacoplan: First Approval. Drugs. 2021 Aug;81 (12) :1423-1430.
Shipping Conditions
Blue Ice
Storage Conditions
-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)
Scientific Category
Peptides
Clinical Information
Phase 3